Normothermic Machine Perfusion Market Size, Share, and Industry Analysis By Offering (Products {Systems and Reagents & Consumables} and Services), By Organ Type (Liver, Lung, Heart, Kidney, and Others), By End-user (Hospitals & ASCs, Specialty Clinics, and Others), and Regional Forecast till 2032

Normothermic machine perfusion is an advanced medical technology utilized for the organ preservation and viability assessment of organs prior to transplantation. This process involves the perfusion of the organ with a warm, oxygenated solution to mimic conditions within the human body, maintaining it at the normal body temperature. This method allows for the proper maintenance and continuous monitoring of organ function, thereby improving overall transplant success rates and reducing the risk of damage.

Normothermic machine perfusion, due to its high potential, is further revolutionizing the field of organ transplantation by increasing the availability of viable organs for patients in need and improving patient outcomes post-transplantation. Therefore, this advanced technology is gaining high significance within the medical field and is expected to become a standard practice in organ preservation and transplantation procedures. This growing significance of normothermic perfusion is expected to surge the market growth in the coming years.

The significant rise in organ transplantation procedures across the globe is further accelerating the demand for normothermic machine perfusion technology. This growing popularity is mainly due to its ability to better maintain organ viability and function as compared to the traditional cold storage methods. This is expected to boost the demand for normothermic machine perfusion products and services for organ preservation and transplantation, driving the market growth over the forthcoming years.

• For instance, in January 2024, according to data published by the U.S. Department of Health & Human Services, a total number of 46,632 organ transplants were recorded in 2023, including both living and deceased donors. This figure indicates an increase in organ transplantation by 8.7% compared to 2022 and 12.7% compared to 2021.

Furthermore, this increase in organ transplantation is primarily influenced by the rising incidence of chronic diseases that can lead to organ failure. Some of these diseases include fatty liver disease and hepatitis C, which results in chronic liver failure. In addition, glomerulonephritis and polycystic kidney disease leads to chronic kidney failure. In such a scenario, there is a higher demand for organ transplantation. Normothermic machine perfusion aids in improving the quality and viability of organs before they are transplanted into a recipient. As a result, its popularity is increasing in several transplant centers across the globe, which is expected to spur market growth during the forecast period.

• For instance, in April 2024, according to World Health Organization (WHO), an estimated 50.0 million individuals are living with chronic hepatitis C virus infection and an estimated 1.0 million new cases occur annually. This high incidence of disease is expected to result in liver failure in several patients requiring organ transplantation. As a result, the high incidence of chronic diseases propelling the number of organ transplants is expected to boost the demand for utilization of normothermic machine perfusion products.

The COVID-19 pandemic had a slight negative impact on the normothermic machine perfusion market. The pandemic drastically affected organ transplantation rates due to factors such as reduced accessibility to healthcare and a significant decrease in the number of organ donations. These factors further resulted in a decreased demand for normothermic machine perfusion products and services, resulting in slow growth during the pandemic.

• For instance, as per data published by the National Center for Biotechnology Information (NCBI) in April 2022, organ transplantation rates experienced a decline of 16.0% in 2020 compared to 2019. This decline led to a decreased demand for utilization of normothermic machine perfusion technology, reducing the sales of products and services.

Key Insights

The report will cover the following key insights:

• Number of Organ Transplantations, by Key Countries, 2023


• Pipeline Analysis, by Key Players


• Recent Product Approvals, by Key Players


• Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others) by Key Players


• Impact of COVID-19 on the Market     

Segmentation

Analysis by Offering

Based on offering, the product segment is expected to hold a significant share of the global normothermic machine perfusion market during the forecast period. The increasing utilization of normothermic machine perfusion products such as systems and reagents & consumables in organ preservation, organ viability assessment, and organ reconditioning is expected to boost the demand for normothermic machine perfusion products. As a result, several prominent market players are involved in the research and development of new products. This will further lead to the introduction of advanced products, increasing its availability and accessibility to healthcare facilities. This is further expected to fuel the segment growth during the forecast period.

• For instance, as of April 2024, a centralized ex vivo lung perfusion (EVLP) service model by Lung Bioengineering is under clinical study to expand the pool of usable donor lungs via this model. Successful results of this clinical study will expand its usage and demand in liver organ preservation and transplantation.

Thus, research and development activities for novel products is expected to boost segment growth.

On the other hand, the services segment is expected to grow substantially during the forecast period. The expansion of organ recovery services by key players to hospitals and transplant centers is expected to surge the demand for normothermic machine perfusion services. Several healthcare facilities are opting for 24/7 access to these services. As a result, the service providers are focused on offering selective access to organ recovery. This is expected to boost the segment growth during the projection period.

Regional Analysis

North America is projected to account for a significant share of the normothermic machine perfusion market during the forecast timeframe. The regional growth is attributed to the increasing geriatric population as the aged individuals are at a higher risk of organ failure compared to the younger individuals. As a result, the increasing elderly population is an important factor affecting the supply and demand for organ transplantation. This is expected to propel the regional market growth.

• For instance, in January 2024, according to the Population Reference Bureau, the number of individuals aged 65 and older is estimated to grow from 58.0 million in 2022 to 82.0 million by 2050 in the U.S.

The Asia Pacific market is projected to expand at a substantial CAGR over the forecast period. The rising awareness regarding organ donation in the region is expected to increase the availability of organs to be preserved. This is expected to increase the number of organ transplants in the region, thereby driving the demand for normothermic machine perfusion and contributing to regional market growth.

• For instance, in December 2023, according to the Indian Ministry of Health and Family Welfare, the government of India held Angdaan Mahotsav to promote awareness programs on organ donation of deceased persons across the country. This initiative to increase awareness is expected to boost the availability of organs, increasing the use of normothermic machine perfusion products and services for organ preservation and transplantation.

Key Players Covered

The report includes the profiles of key players such as OrganOx Limited, XVIVO, TransMedics, Inc., and Lung Bioengineering.

Key Industry Developments

• In December 2023, XVIVO announced the launch of the pilot project in NRP (normothermic regional perfusion). The company launched this project considering the promising business potential with significant interest in NRP (normothermic regional perfusion) as an organ recovery method in the U.S.


• In January 2023, OrganOx Limited announced the recruitment of the first U.S. patient into its post-approval study (PAS) with metra, its fully automated normothermic machine perfusion (NMP) system for liver transplantation.

In December 2021, OrganOx Limited announced that it received the U.S. FDA pre-market (PMA) approval for its metra system to preserve and transport donor livers destined for transplantation in recipients.